Brentuximab vedotin with chemotherapy (BrECADD) for previously untreated advanced classical Hodgkin lymphoma

Hodgkin lymphoma (HL) is an uncommon cancer that develops in the lymphatic system, which is a network of vessels and glands spread throughout the body. About 95% of all HL cases are classical HL. Lymphomas are cancers that occur if white blood cells of the immune system start to multiply uncontrollably. Symptoms of classical HL include swelling of lymph nodes in the neck, armpit or groin, recurring fever, night sweats, weight loss, cough, breathlessness, abdominal pain and itching. There is an unmet need for treatment strategies which improve survival outcomes that are not offset by more serious treatment side-effects.
Brentuximab vedotin is delivered via intravenous infusion and